Aileron Raises $10 Million

Robert Buderi4/15/08

Cambridge-based biopharmaceutical company Aileron Therapeutics, which is developing peptide drugs for the treatment of cancer and other diseases, has raised $10 million in a private placement of preferred stock, the company announced today. Apple Tree Partners and the Novartis Venture Fund led the round.

Bob is Xconomy's founder and editor in chief. You can e-mail him at bbuderi@xconomy.com, call him at 617.500.5926, or follow him on Twitter at http://twitter.com/bbuderi.